New DUROLANE Agreement

Bioventus entered into an agreement with Galderma to bring DUROLANE knee osteoarthritis treatment to the U.S., and plans to file a Premarket Approval Application with FDA in early 2017.

Galderma manufactures DUROLANE and other hyaluronic acid products. Bioventus purchased the ex-U.S. assets of DUROLANE in 2014, and has...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us